louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00207480: Brief, Behavioral Intervention to Reduce Douching Among Adolescent and Young Women
Official title: Brief, Behavioral Intervention to Reduce Douching Among Adolescent and Young Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vaginal Douching
Bacterial Vaginosis
Lead sponsor: Centers for Disease Control and Prevention
Sponsor class: FED
Collaborators: name: Tulane University School of Public Health and Tropical Medicine
First posted: 2005-09-21
Enrollment: 0
Sex: FEMALE
Minimum age (years): 16
Maximum age (years): 24
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: OTHER

Brief summary: This study will implement and test a brief, tailored individual-level intervention to be used in two New Orleans adolescent clinics with female patients aged 16-24 who douche.

Detailed description: The study implements a client-centered behavioral intervention (CCBI) based on Prochaska's Transtheoretical Model of Change (TMC) and the intervention will use Miller's Motivational Interviewing (MI) techniques. This intervention will be evaluated using (1) an audio/computer-assisted self-administered interview (ACASI) survey to assess changes in respondents' douching knowledge, attitudes, and practices, and (2) biological testing for Bacterial Vaginosis.

Eligibility criteria: Inclusion Criteria:

* Women attending between the ages of 16 and 24 who have douched at least once in the last 180 days, agree to a test for Bacterial Vaginosis, and agree to allow us to contact you by telephone or in person for a follow-up interview and testing for bacterial vaginosis.

Exclusion Criteria:

* currently pregnant, non-English speaking

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New Orleans
country: United States
facility: Orleans Women's Health Clinic
state: Louisiana
Study officials:
affiliation: Tulane University School of Public Health and Tropical Medicine
name: Patricia Kissinger, PhD, RN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04602780: Evaluating the Revised WORQ in CI Users
Official title: Evaluating the Revised Work Rehabilitation Questionnaire in Cochlear Implant Users
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hearing Loss
Keywords: Work Rehabilitation Questionnaire
International Classification of Functioning, Disability and Health
Cochlear Implantation
Lead sponsor: University Hospital, Antwerp
Sponsor class: OTHER
Collaborators: name: World Hearing Centre
name: Hospital Universitario La Paz
name: Fiona Stanley Hospital
name: Wuerzburg University Hospital
First posted: 2020-10-26
Enrollment: 177
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Experienced adult CI users

Brief summary: The Work Related Questionnaire (WORQ) is a 59-item questionnaire of which each item represents an International Classification of Functioning and disability category. The WORQ was modified and reduced to include only questions relevant to Cochlear Implant (CI) users. In this analysis, a multicentre retrospective review of the revised WORQ in CI users was performed, with the revised WORQ as part of the questionnaires used in the regular clinical follow-up of CI users. Experienced CI users' responses on the questions will be evaluated to define the qualifiers for the revised WORQ.


Eligibility criteria: Inclusion Criteria:

* Adults over the age of 18 years
* Adults must wear a MED-EL cochlear implant
* Adults may have the following hearing indications and device fitting:

  * Unilateral cochlear implant with severe-to-profound hearing loss
  * Bilateral cochlear implant with severe-to-profound hearing loss
  * Single sided deafness (SSD) where the poorer ear PTA ≥70 dB HL and the better ear PTA ≤30 dB HL with an interaural threshold gap of ≥40 dB HL.
  * Asymmetrical hearing loss using a cochlear implant in the poorer ear and a hearing aid in the better ear (also known as bimodal fitting). The poorer ear PTA ≥70 dB HL and the better ear PTA \>30 dB HL and ≤55 dB HL with an interaural threshold gap of ≥15 dB HL.
* Adults should have a minimum of one year's device experience

Exclusion Criteria

No extra exclusion criteria

Primary outcomes:
measure: Completion of the WORQ questionnaire
timeFrame: One test interval, at least one year after Cochlear Implantation
Secondary outcomes:
Other outcomes:
Locations:
city: Perth
country: Australia
facility: Fiona Stanley Fremantle Hospital Group
city: Edegem
country: Belgium
facility: University Hospital Antwerp
city: Würzburg
country: Germany
facility: University Clinic of Würzburg
city: Kajetany
country: Poland
facility: World Hearing Centre
city: Madrid
country: Spain
facility: Hospital La Paz
Study officials:
References:
Clinical trial NCT00215280: Epidemiology and Control of Mansonella Perstans Infection in Uganda
Official title: Studies on the Epidemiology and Control of Mansonella Perstans Infection in Uganda
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mansonelliasis
Pruritus
Lymphoedema
Abdominal Pains
Keywords: Mansonella perstans
microfilaraemia
ivermectin
albendazole
Uganda
Lead sponsor: DBL -Institute for Health Research and Development
Sponsor class: OTHER
Collaborators: name: Ministry of Health, Uganda
First posted: 2005-09-22
Enrollment: 1000
Sex: ALL
Minimum age (years): 5
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available. The study aims at providing data on diagnostic, epidemiological, morbidity and treatment aspects of M. perstans infections in Uganda.

Detailed description: Overall objective: to investigate diagnostic, epidemiological and treatment aspects of M. perstans in Uganda with relevance to control

Specific objectives:

1. To establish the pattern of diurnal periodicity of M. perstans microfilaraemia in humans
2. To establish the patterns of M. perstans microfilaraemia and possible clinical manifestations related to this infection in two communities with medium to high endemicity
3. To determine the efficacy of ivermectin alone and the combination of ivermectin and albendazole on M. perstans microfilaraemia.

Eligibility criteria: Inclusion Criteria:

* Individuals \>= 5 years with or without M. perstans infection

Exclusion Criteria:

* Individuals \< 5 years
* Pregnant women

Primary outcomes:
measure: microfilariae periodicity patterns
measure: epidemiology of M. perstans at community level
measure: clinical spectre among infected
measure: reduction in microfilaraemia
Secondary outcomes:
measure: treatment effect on clinical manifestations
Other outcomes:
Locations:
city: Luwero and Mukono
country: Uganda
facility: Luwero
state: Luwero and Mukono Districts
Study officials:
affiliation: Ministry of Health, Uganda
name: Asanta M Asio, Msc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Asio SM, Simonsen PE, Onapa AW. A randomised, double-blind field trial of ivermectin alone and in combination with albendazole for the treatment of Mansonella perstans infections in Uganda. Trans R Soc Trop Med Hyg. 2009 Mar;103(3):274-9. doi: 10.1016/j.trstmh.2008.10.038. Epub 2008 Dec 9.
citation: Asio SM, Simonsen PE, Onapa AW. Mansonella perstans filariasis in Uganda: patterns of microfilaraemia and clinical manifestations in two endemic communities. Trans R Soc Trop Med Hyg. 2009 Mar;103(3):266-73. doi: 10.1016/j.trstmh.2008.08.007. Epub 2008 Sep 21.
Clinical trial NCT07002580: Evaluation of the Effectiveness of iPACK and Adductor Canal Blocks on Patients Undergoing Arthroscopic Knee Surgery
Official title: Evaluation of the Effectiveness of iPACK (Local Anesthetic Infiltration of the Interspace Between the Popliteal Artery and the Posterior Knee Capsule) and Adductor Canal Blocks on Quality of Recovery in Patients Undergoing Arthroscopic Knee Surgery
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Patients Undergoing Arthroscopic Knee Surgery
Keywords: Arthroscopic Knee Surgery
Perifheric Nerve Block
Analgesia
iPACK
Adductor Canal Block
QoR-15
Lead sponsor: Sakarya University
Sponsor class: OTHER
First posted: 2025-06-03
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Arthroscopic knee surgery is one of the most commonly performed procedures in orthopedic surgery. More than 50% of patients experience moderate to severe pain after the operation. Inadequate postoperative pain control and poor recovery quality can negatively impact physiotherapy protocols, prolong hospital stays, and consequently lead to cognitive dysfunction, systemic infections, and increased healthcare costs.

Therefore, reducing postoperative pain and improving recovery quality are of great importance. In our clinic, a variety of analgesic techniques are routinely employed as part of a multimodal analgesia approach for patients undergoing arthroscopic knee surgery. One of these techniques is the simultaneous application of the IPACK block and the adductor canal block.

In this study, we aim to evaluate the effectiveness of these blocks on postoperative recovery quality in patients undergoing arthroscopic knee surgery.


Eligibility criteria: Inclusion Criteria:

* Patients aged between 18 and 50 years,
* Scheduled for arthroscopic knee surgery under spinal anesthesia due to knee pathology
* Patients classified as ASA physical status I-II-III according to the American Society of Anesthesiologists risk classification

Exclusion Criteria:

* Coagulopathy
* ASA IV-V patients
* Uncooperable patients
* Patients who refuses to participate in study
* Patients who takes chronic pain treatments

Primary outcomes:
measure: Quality of Recovery
timeFrame: 24 hours.
Secondary outcomes:
measure: Analgesic Consumption
timeFrame: 24 hours.
Other outcomes:
Locations:
city: Sakarya
country: Turkey
facility: Sakarya University Training and Research Hospital
Study officials:
References:
Clinical trial NCT01394380: Reduction of Sweetened Beverages and Intrahepatic Fat
Official title: Effects of a Reduction of Sweetened Beverages Consumption in Overweight High Consumers on Cardiometabolic Risk Factors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Dyslipidemia
Metabolic Syndrome
Keywords: sugar
sweetened beverages
hepatic steatosis
visceral obesity
metabolic syndrome
Lead sponsor: University of Lausanne
Sponsor class: OTHER
Collaborators: name: Centre Hospitalier Universitaire Vaudois
name: Insel Gruppe AG, University Hospital Bern
First posted: 2011-07-14
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The study will enroll 68 overweight male and female subjects with a high (\> 2 3dl-can soda/day) consumption of sweetened beverage per day. After a run-in period of 4 weeks, subjects will be randomized to either a 12-week intervention arm in which sweetened beverages will be replaced by artificially sweetened, calorie-free beverages, or to a control arm. The following measurements will be performed at the end of the run-in period and at the end of the intervention period

* intrahepatic fat concentration
* visceral fat volume
* changes in day-long metabolic profile from baseline(plasma glucose, insulin, and triglyceride concentrations)
* changes in food intake and daily energy, carbohydrate and sugars intake from baseline


Eligibility criteria: Inclusion Criteria:

* gender male or female
* body mass index (BMI) \> 27 kg/m2 consumption of \> 2 3dl-can regular soda/day
* low to moderate physical activity (\< 60 min walking/day; \< 3 exercise session/week

Exclusion Criteria:

* diabetes mellitus
* liver, kidney or heart disease
* any current drug treatment
* contra-indications to MR examination (pacemaker, foreign bodies,etc)
* pregnancy or planned pregnancy
* active weight gain or weight loss (weight change \> 4 kg in the past 12 months)
* consumption of drugs or illicit substances
* consumption of more than 10g alcohol/day
* vegetarians or subjects on special diets

Primary outcomes:
measure: changes in intrahepatic fat concentration
timeFrame: at the end of run-in and after 12 weeks intervention/control
Secondary outcomes:
measure: changes in visceral fat volume
timeFrame: at the end of run-in and after 12 weeks of intervention/control
measure: changes in day-long metabolic profile
timeFrame: at the end of run-in and after 12 weeks of intervention/control
measure: changes in food intake from baseline
timeFrame: at the end of the run-in period and after 6, and 12 weeks of intervention/control
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: Clinical Research Center, CHUV
state: VD
Study officials:
affiliation: Department of Physiology, University of Lausanne
name: Luc Tappy, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01422980: Effect of Consumption of Dairy Product on Upper Gastric Discomfort
Official title: Effect of Consumption of Dairy Product on Upper Gastric Discomfort
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Upper Gastric Discomfort
Keywords: dairy product
upper gastric discomfort
adult
Lead sponsor: Danone Global Research & Innovation Center
Sponsor class: INDUSTRY
First posted: 2011-08-25
Enrollment: 236
Sex: ALL
Minimum age (years): 21
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine whether the consumption of test dairy products is effective in reducing upper gastric discomfort after 2 weeks of product consumption.


Eligibility criteria: Inclusion Criteria:

* Male and female
* 21 - 60 years old
* Experiencing upper gastric discomfort

Exclusion Criteria:

* Participants with alarm symptoms (dysphagia, bleeding, involuntary weight loss clinically significant \>10% of it habitual weight during the last 6 months).
* Participants with diagnosed severe organic esophageal medical history (endoscopic eosophagitis A, B, C or D of Los Angeles classification, peptic stenosis, Barrett oesophagus, huge hiatus hernia or para-esophageal) gastric or duodenal ulcer or high digestive haemorrhage clinical history.

Primary outcomes:
measure: Change in gastro-oesophageal symptoms as assessed by RDQ questionnaire
timeFrame: Two timepoints are considered in the assessment of the change outcome measures: from Baseline (before product consumption) to Endpoint (i.e. final evaluation visit after 2 weeks of product consumption)
Secondary outcomes:
Other outcomes:
Locations:
city: BuenosAires
country: Argentina
facility: Hospital Italiano
Study officials:
References:
Clinical trial NCT04542980: Qualitative Evaluation of Tear Fluid and Blood for Auto Antibodies Produced in Response to COVID-19
Official title: Qualitative Evaluation of Tear Fluid and Blood for IgM and IgG Produced in Response to SARS-CoV2, the Virus Responsible for COVID-19.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: SARS-CoV 2 Infection
Covid19
Lead sponsor: Namida Lab
Sponsor class: INDUSTRY
First posted: 2020-09-09
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study participants will be recruited from hospital and health care settings testing and/or treating individuals for the presence of the SARS-CoV2 virus and resulting COVID-19 disease.

Brief summary: This study objective is to collect tear and blood samples from individuals with positive SARS-COV2 diagnosis and test those samples for the presence of various SARS-COV2 viral antigens and autoantibodies.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older Has been tested for SARS-CoV2 and awaiting results Sample collection for SARS-CoV2 testing Tested positive for SARS-CoV2 virus (confirmed by RT-PCR) prior to enrollment

Exclusion Criteria:

* Under 18 years of age Concurrent eye infection or trauma unrelated to presence of SARS-CoV2 virus. Advanced COVID-19 state what would preclude safe and feasible sample collection.

Primary outcomes:
measure: Qualitative assessment of IgM and/or IgG by indirect ELISA assay.
timeFrame: through study completion, up to 8 months
Secondary outcomes:
Other outcomes:
Locations:
city: Fayetteville
country: United States
facility: Namida Lab
state: Arkansas
Study officials:
References:
Clinical trial NCT03146780: Digital vs Conventional Impressions Study
Official title: Clinical Evaluation of Digital Versus Conventional Impressions Part I: Marginal and Internal Fit
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Prosthesis
Lead sponsor: University of Rochester
Sponsor class: OTHER
First posted: 2017-05-10
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study aims to compare how a single cap best fit on a tooth that is fabricated with digital and conventional impression techniques.


Eligibility criteria: Inclusion Criteria:

* Age of patient ≥ 18 years old
* Good oral hygiene and compliance
* In need of a single full-coverage crown on any vital premolar or first molar tooth
* Opposing tooth is free of indirect restoration (crown)
* Asymptomatic tooth free of pathology
* No requirement for additional treatment (endodontic treatment, post and core, crown lengthening)
* Anticipated supragingival or equigingival crown margin
* Anticipated crown margin on natural tooth structure
* Adequate abutment height after tooth preparation (minimum 4mm)

Exclusion Criteria:

* Age of patient less than 18 years old
* Poor oral hygiene and calculus on sample teeth
* In need of a single full-coverage crown on tooth other than a vital premolar or first molar tooth
* Opposing tooth is restored with indirect restoration
* Periapical or periodontal pathology
* Anticipated pulp exposure or need for additional treatment (endodontic treatment, post and core, crown lengthening)
* Anticipated subgingival crown margin
* Anticipated crown margin on direct restoration
* Inadequate abutment height after tooth preparation

Primary outcomes:
measure: Number of participants with a correctly fitted prosthesis
timeFrame: From impression stage to crown delivery, approximately four weeks. There are no follow up visits once crown is delivered.
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester
state: New York
Study officials:
References:
Clinical trial NCT02005380: Usability Study of Spaced Retrieval Exercise Using Mobile Devices for Alzheimer's Disease Rehabilitation
Official title: Usability Study of Spaced Retrieval Exercise Using Mobile Devices for Alzheimer's Disease Rehabilitation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Alzheimer's Disease
Keywords: Alzheimer's Disease Rehabilitation
Lead sponsor: German-Jordanian University
Sponsor class: OTHER
First posted: 2013-12-09
Enrollment: 20
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Darat Samir Shamma, a senior residential care facility and

Brief summary: The focus of this work is to explore the use of modern mobile technology to enable people with Alzheimer's disease to improve their abilities to perform activities of daily living and hence to promote independence and participation in social activities. This work also aims at reducing the burden on caregivers by increasing the AD patients' sense of competence and ability to handle behavior problems.

Detailed description: The investigators developed ADcope, an integrated application that includes several modules that target individuals with Alzheimer's disease , using mobile devices. The investigators developed two different user interfaces: a text-based and a graphic-based. To evaluate the usability of the application, participants with early stages of AD were asked to run the two user interfaces of the spaced retrieval memory exercise using a tablet mobile device.

Eligibility criteria: Inclusion Criteria:

- Have early stages of Alzheimer's decease

Primary outcomes:
measure: NASA Task Load Index Measure
timeFrame: 1 hour
Secondary outcomes:
measure: Test Score
timeFrame: 1 Hour
Other outcomes:
Locations:
city: Amman
country: Jordan
facility: Darat Samir Shamma
Study officials:
affiliation: German-Jordanian University
name: Ahmad Zmily, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04506580: Comparison of Postoperative Wound Between Dermabond Prineo(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) and Subcuticular Suture in Simultaneous Total Knee Arthroplasty
Official title: Comparison of Postoperative Wound Between Dermabond PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) and Subcuticular Suture in Simultaneous Total Knee Arthroplasty
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Osteoarthritis, Knee Cutaneous Suture, Dermabond, Subcuticular Suture
Lead sponsor: The Catholic University of Korea
Sponsor class: OTHER
First posted: 2020-08-10
Enrollment: 50
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to compare the clinical results of postoperative wound between Dermabond PRINEO™(2-octyl Cyanoacrylate adhesive and polyester mesh) and subcuticular suture in simultaneous total knee arthroplasty

There is previous studies over whether or not to use skin adhesive material is superior or inferior to subcuticular suture This study prospectively randomized patients receiving bilateral total knee arthroplasty(TKA). Patients preference and clinical results was investigated in both knee of same patients who received skin adhesive or subcuticular suture in each knee.


Eligibility criteria: Inclusion Criteria:

* Patients for total knee arthroplasty
* having medicare insurance

Exclusion Criteria:

* Rheumatoid arthritis
* Other inflammatory arthritis
* Neuropsychiatric patients
* Allergy or intolerance to study material
* Patients with an American Society of Anesthesiologists(ASA) score of IV (angina, congestive heart failure, dementia, cerebrovascular accident)

Primary outcomes:
measure: wound Hypertrophy scale at postoperative 6 month
timeFrame: at postoperative 6 months
Secondary outcomes:
measure: Skin closure time
timeFrame: operation day
measure: wound complication
timeFrame: postoperative 2 weeks
measure: wound complication
timeFrame: postoperative 6 weeks
measure: wound complication
timeFrame: postoperative 3 month
measure: wound complication
timeFrame: postoperative 6 month
measure: Stitch out time
timeFrame: postoperative 2 weeks
measure: Stitch out visual visual analogue scale(VAS)
timeFrame: postoperative 2 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul St. Mary's Hospital
Study officials:
affiliation: the Catholic Univerisity of Korea Seoul St Mary's hospital
name: Yong In, MD, PhD
role: STUDY_CHAIR
References: